A Hyaluronic Acid−Taxol Antitumor Bioconjugate Targeted to Cancer Cells
Authors:
- 25 March 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 1 (2) , 208-218
Abstract
A cell-targeted polymeric prodrug prepared from Taxol and chemically modified hyaluronic acid (HA) was evaluated in vitro. Herein we report four results in support of the selective uptake and targeted toxicity of the HA−Taxol prodrug. First, a fluorescently labeled HA−Taxol (FITC−HA−Taxol) was synthesized and used to demonstrate cell-specific binding and uptake using flow cytometry and confocal microscopy. Second, the selective cytotoxicity of FITC−HA−Taxol allowed direct correlation of uptake with selective cytotoxicity. Third, the rapid uptake and selective cytotoxicity of HA-Taxol bioconjugates could be blocked by either excess HA or by an anti-CD44 antibody, but not by chondroitin sulfate (CS). Finally, the release of free Taxol from HA−Taxol in human plasma or in cell culture media revealed that the free drug was hydrolytically released from the bioconjugate by cleavage of the labile 2‘ ester linkage. Taken together, these data support the notion that the targeted cytotoxicity of HA−Taxol bioconjugates requires receptor-mediated cellular uptake of the bioconjugate followed by hydrolytic release of free Taxol.Keywords
This publication has 34 references indexed in Scilit:
- Fluorescence-labeled-hyaluronan loading test as an index of hepatic sinusoidal endothelial cell function in the ratInternational Hepatology Communications, 1996
- Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activityJournal of Drug Targeting, 1996
- Cell-Based Screen for Identification of Inhibitors of Tubulin PolymerizationJournal of Natural Products, 1996
- Carbohydrate-Protein Interactions in Vascular BiologyAnnual Review of Cell and Developmental Biology, 1995
- Hyaluronidases - a group of neglected enzymesProtein Science, 1995
- Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation.Journal of Experimental Medicine, 1995
- Role of CD44 cytoplasmic domain in hyaluronan bindingEuropean Journal of Immunology, 1995
- Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: Correlation with invasive potentialJournal of Cellular Physiology, 1994
- Antibody‐induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibodyEuropean Journal of Immunology, 1993
- The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan.Journal of Cell Biology, 1992